Is Daiichi Sankyo Company, Limited a good investment? Daiichi Sankyo Company, Limited (4568.T) is currently trading at 2857.50 JPY. Market analysts have a consensus price target of 4021.25 JPY. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 18.29. This valuation is generally in line with the broader market.
Earnings Schedule: Daiichi Sankyo Company, Limited is expected to release its next earnings report on Jan. 29, 2027. The market consensus estimate for Forward EPS is 143.56.
For income investors, Daiichi Sankyo Company, Limited pays a dividend yield of 3.08%. With a payout ratio of 51%, the dividend appears sustainable.
Yes, it pays an annual dividend of 89.00 JPY (3.08% yield).
Daiichi Sankyo Company, Limited is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be Jan. 29, 2027. The company currently has a trailing EPS of 153.05.
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.
| Year | Total Dividends |
|---|---|
| ▸2027 |
50.00 JPY
|
| June 23, 2027 | 50.0000 |
| ▸2026 |
89.00 JPY
|
| Dec. 10, 2026 | 50.0000 |
| June 23, 2026 | 39.0000 |
| ▸2025 |
69.00 JPY
|
| Dec. 10, 2025 | 39.0000 |
| June 24, 2025 | 30.0000 |
| ▸2024 |
60.00 JPY
|
| Dec. 10, 2024 | 30.0000 |
| June 18, 2024 | 30.0000 |
| ▸2023 |
35.00 JPY
|
| Dec. 8, 2023 | 20.0000 |
| June 20, 2023 | 15.0000 |
| ▸2022 |
27.00 JPY
|
| Dec. 1, 2022 | 13.5000 |
| June 28, 2022 | 13.5000 |
| ▸2021 |
27.00 JPY
|
| Dec. 1, 2021 | 13.5000 |
| June 22, 2021 | 13.5000 |
| ▸2020 |
75.50 JPY
|
| Dec. 1, 2020 | 40.5000 |
| June 16, 2020 | 35.0000 |
| ▸2019 |
70.00 JPY
|
| Dec. 2, 2019 | 35.0000 |
| June 18, 2019 | 35.0000 |
| ▸2018 |
70.00 JPY
|
| Dec. 3, 2018 | 35.0000 |
| June 19, 2018 | 35.0000 |
| ▸2017 |
70.00 JPY
|
| Dec. 1, 2017 | 35.0000 |
| June 20, 2017 | 35.0000 |
| ▸2016 |
65.00 JPY
|
| Sept. 28, 2016 | 35.0000 |
| March 29, 2016 | 30.0000 |
| ▸2015 |
40.00 JPY
|
| Sept. 28, 2015 | 10.0000 |
| March 27, 2015 | 30.0000 |
| ▸2014 |
60.00 JPY
|
| Sept. 26, 2014 | 30.0000 |
| March 27, 2014 | 30.0000 |
| ▸2013 |
60.00 JPY
|
| Sept. 26, 2013 | 30.0000 |
| March 27, 2013 | 30.0000 |
| ▸2012 |
60.00 JPY
|
| Sept. 26, 2012 | 30.0000 |
| March 28, 2012 | 30.0000 |
| ▸2011 |
60.00 JPY
|
| Sept. 28, 2011 | 30.0000 |
| March 29, 2011 | 30.0000 |
| ▸2010 |
60.00 JPY
|
| Sept. 28, 2010 | 30.0000 |
| March 29, 2010 | 30.0000 |
| ▸2009 |
70.00 JPY
|
| Sept. 25, 2009 | 30.0000 |
| March 26, 2009 | 40.0000 |
| ▸2008 |
75.00 JPY
|
| Sept. 25, 2008 | 40.0000 |
| March 26, 2008 | 35.0000 |
| ▸2007 |
65.00 JPY
|
| Sept. 25, 2007 | 35.0000 |
| March 27, 2007 | 30.0000 |
| ▸2006 |
55.00 JPY
|
| Sept. 26, 2006 | 30.0000 |
| March 28, 2006 | 25.0000 |
| ▸2005 |
75.00 JPY
|
| March 28, 2005 | 75.0000 |
| ▸2004 |
22.50 JPY
|
| Sept. 27, 2004 | 15.0000 |
| March 26, 2004 | 7.5000 |
| ▸2003 |
20.00 JPY
|
| Sept. 25, 2003 | 10.0000 |
| March 26, 2003 | 10.0000 |
| ▸2002 |
15.00 JPY
|
| Sept. 25, 2002 | 12.5000 |
| March 26, 2002 | 2.5000 |
| ▸2001 |
14.75 JPY
|
| Sept. 25, 2001 | 2.5000 |
| March 27, 2001 | 12.2500 |
| ▸2000 |
24.50 JPY
|
| Sept. 26, 2000 | 12.2500 |
| March 28, 2000 | 12.2500 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Daiichi Sankyo Company, Limited | Jun 23, 2027 | Upcoming | 50.0 JPY |
| Daiichi Sankyo Company, Limited | Dec 10, 2026 | Upcoming | 50.0 JPY |
| Daiichi Sankyo Company, Limited | Jun 23, 2026 | Paid | 39.0 JPY |
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 29, 2020 | 3:1 |
Community Discussion